Evidence map›Paper›PMID 23571270›Full record

ArticleCellular signalling2013

CB₁ cannabinoid receptors promote maximal FAK catalytic activity by stimulating cooperative signaling between receptor tyrosine kinases and integrins in neuronal cells.

George D Dalton, Lynda J Peterson, Allyn C Howlett

Abstract read
In one paragraph

Article in Cellular signalling, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 31 citations in OpenAlex.

  1. The how and why for multiple forms of hippocampal LTP.Frontiers in synaptic neuroscience · 2026
    Review
  2. Article
  3. Article
  4. Cannabinoid CBCell death & disease · 2022
    Article
  5. Review
  6. Review
  7. CBFrontiers in cellular neuroscience · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. CBAdvances in pharmacology (San Diego, Calif.) · 2017
    Review
  14. Mouse Neuroblastoma CBMethods in enzymology · 2017
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

George D DaltonDepartment of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. gedalton@wakehealth.edu
Lynda J Peterson
Allyn C Howlett
Wake Forest University · USUniversity of North Carolina at Chapel Hill · US

Funding

CANNABINOID RECEPTORS IN NEURONAL CELLS AND BRAINR01DA003690 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HOWLETT, ALLYN C · 1985 to 2014
$2.8M
CB1 Receptor-Mediated Tyrosine Phosphorylation of FAK and ERK in NeuronsF32DA026295 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DALTON, GEORGE D · 2010 to 2012
$170k
NIDA NIH HHS F32 DA026295NIDA NIH HHS F32-DA026295NIDA NIH HHS R01 DA003690NIDA NIH HHS R01-DA03690
6 · The paper itself

Abstract

Tyrosine phosphorylation (Tyr-P) of focal adhesion kinase (FAK) regulates FAK activation. Phosphorylated FAK Tyr 397 binds Src family kinases (Src), which in turn directly phosphorylate FAK Tyr 576/577 to produce maximal FAK enzymatic activity. CB₁ cannabinoid receptors (CB₁) are abundantly expressed in the nervous system and influence FAK activation by presently unknown mechanisms. The current investigation determined that CB₁-stimulated maximal FAK catalytic activity is mediated by Gi/o proteins in N18TG2 neuronal cells, and that G12/13 regulation of Rac1 and RhoA occurs concomitantly. Immunoblotting analyses using antibodies against FAK phospho-Tyr 397 and phospho-Tyr 576/577 demonstrated that the time-course of CB₁-stimulated FAK 576/577 Tyr-P occurred in three phases: Phase I (0-2 min) maximal Tyr-P, Phase II (5-20 min) rapid decline in Tyr-P, and Phase III (>20 min) plateau in Tyr-P at submaximal levels. In contrast, FAK 397 Tyr-P was monophasic and significantly lower in magnitude. FAK 397 Tyr-P and Phase I FAK 576/577 Tyr-P involved protein tyrosine phosphatase (PTP1B and Shp1/Shp2)-mediated Src activation, Protein Kinase A (PKA) inhibition, and integrin activation. Phase I maximal FAK 576/577 Tyr-P also required cooperative signaling between receptor tyrosine kinases (RTKs) and integrins. The integrin antagonist RGDS peptide, Flk-1 vascular endothelial growth factor receptor (VEGFR) antagonist SU5416, and epidermal growth factor receptor (EGFR) antagonist AG 1478 blocked Phase I FAK 576/577 Tyr-P. CB₁ agonists failed to stimulate FAK Tyr-P in the absence of integrin activation upon suspension in serum-free culture media. In contrast, cells grown on the integrin ligands fibronectin and laminin displayed increased FAK 576/577 Tyr-P that was augmented by CB₁ agonists and blocked by the Src inhibitor PP2 and Flk-1 VEGFR antagonist SU5416. Taken together, these studies have identified a complex integrative pathway utilized by CB₁ to stimulate maximal FAK 576/577 Tyr-P in neuronal cells.

Indexed as

AnimalsBenzoxazinesCell Line, TumorErbB ReceptorsFibronectinsFocal Adhesion Protein-Tyrosine KinasesIntegrinsKineticsLamininMiceMorpholinesNaphthalenesNeuronsOligopeptidesPertussis ToxinPhosphorylation(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanonearginyl-glycyl-aspartic acidBenzoxazinesErbB ReceptorsFibronectinsFocal Adhesion Protein-Tyrosine KinasesIntegrinsLamininMorpholinesNaphthalenesOligopeptidesPertussis ToxinProtein Tyrosine Phosphatase, Non-Receptor Type 1Protein Tyrosine Phosphatase, Non-Receptor Type 11Protein Tyrosine Phosphatase, Non-Receptor Type 6Ptpn1 protein, mouseReceptor, Cannabinoid, CB1RNA, Small Interferingsrc-Family KinasesVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID23571270
PMCPMC4165595
OpenAlexW1978847105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.